Serina Therapeutics posts investor deck outlining POZ platform, lead Parkinson’s candidate SER-252 Phase 1b study
SERA•Balance sheet update
The balance sheet update cited $21.2 million private placement gross proceeds; $24.5 million cash at March 31, 2026; and $5.2 million additional gross proceeds received in April.
Phase 1b study and regulatory plan
SER-252 Phase 1b registrational study is underway; first patient dosed February 2026; SAD Cohort 1 (n=8) dosing completed July 2026.
Blinded safety, tolerability, PK review for SAD Cohort 1 is scheduled for August 2026; SAD topline data is targeted for 1Q 2027.
The regulatory plan targets a 505(b)(2) NDA.
Investor deck highlights POZ platform and SER-252 program
Serina outlined a milestone-driven CNS strategy centered on lead program SER-252, a POZ-apomorphine product candidate for advanced Parkinson’s disease.
The company said SER-252 is designed for controlled release with an on-body enFuse device, aiming for twice-weekly dosing.
